OncoPrecision is developing high-throughput screening technologies that can accurately predict cancer patients' response to a wide range of therapies and modalities in clinically-relevant turnaround times with the goal of dramatically improving cancer patient outcomes. The company is based in New York, NY and Cordoba, Argentina.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/31/22 | $3,300,000 | Seed |
Creative Ventures Fundacion Para el Progreso de la Medicina GRIDX New York Ventures SOSV | undisclosed |
